Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014

Dateline City: WHITEHOUSE STATION, N.J. KEYTRUDA® monotherapy achieved 24 percent overall response rate in patients with PD-L1 positive, advanced bladder (urothelial) cancer Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA® (pembrolizumab) – the company’s anti-PD-1 therapy – in PD-L1 positive, advanced urothelial cancer (also known as bladder cancer). Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News Source Type: news